Ariad Pharmaceuticals Inc. (NASDAQ:ARIA) will report its next earnings on Feb 21 – Feb 27 (Est.). The company reported the earnings of $-0.14/Share in the last quarter where the estimated EPS by analysts was $-0.19/share. The difference between the expected and actual EPS was $0.05/share, which represents an Earnings surprise of 26.3%.
Many analysts are providing their Estimated Earnings analysis for Ariad Pharmaceuticals Inc. and for the current quarter 10 analysts have projected that the stock could give an Average Earnings estimate of $-0.18/share. These analysts have also projected a Low Estimate of $-0.21/share and a High Estimate of $-0.12/share.
In case of Revenue Estimates, 10 analysts have provided their consensus Average Revenue Estimates for Ariad Pharmaceuticals Inc. as 46.11 Million. According to these analysts, the Low Revenue Estimate for Ariad Pharmaceuticals Inc. is 42.5 Million and the High Revenue Estimate is 58.8 Million. The company had Year Ago Sales of 36.5 Million.
Some buy side analysts are also providing their Analysis on Ariad Pharmaceuticals Inc., where 3 analysts have rated the stock as Strong buy, 2 analysts have given a Buy signal, 4 said it’s a HOLD, 2 reported it as Underperform and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)
When it comes to the Analysis of a Stock, Price Target plays a vital role. 10 Analysts reported that the Price Target for Ariad Pharmaceuticals Inc. might touch $22 high while the Average Price Target and Low price Target is $13.05 and $7 respectively.
To analyze a stock, one should look for Upgrades and Downgrades of a stock. Ariad Pharmaceuticals Inc. got Initiated on 3-Nov-16 where investment firm Deutsche Bank Initiated the stock to Hold.
Ariad Pharmaceuticals Inc. closed its last trading session at $13.7 with the gain of 0.73%. The Market Capitalization of the company stands at 2.68 Billion. The Company has 52-week high of $14.42 and 52-week low of $4.37. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is 17.51% where SMA50 and SMA200 are 14.58% and 55.07% respectively. The Company Touched its 52-Week High on Oct 10, 2016 and 52-Week Low on Feb 11, 2016.
The Relative Volume of the company is 1.16 and Average Volume (3 months) is 7.43 million. Ariad Pharmaceuticals Inc. P/E (price to earnings) ratio is 0 and Forward P/E ratio of 0.
The company shows its Return on Assets (ROA) value of -5.4%. The Return on Equity (ROE) value stands at 37.1%. While it’s Return on Investment (ROI) value is -62.9%.
While looking at the Stock’s Performance, Ariad Pharmaceuticals Inc. currently shows a Weekly Performance of 1.4%, where Monthly Performance is 57.18%, Quarterly performance is 32.31%, 6 Months performance is 56.29% and yearly performance percentage is 115.29%. Year to Date performance value (YTD perf) value is 120.8%. The Stock currently has a Weekly Volatility of 5.23% and Monthly Volatility of 5.60%.